Semantic Scholar uses AI to extract papers important to this topic.
Hepatitis B virus (HBV) infection remains a global public health problem with changing epidemiology due to several factors… Expand Chronic hepatitis B virus (HBV) infection leads to cirrhosis and hepatocellular carcinoma (HCC). Antiviral agents are thought to… Expand Large volume of new data on the natural history and treatment of chronic hepatitis B virus (HBV) infection have become available… Expand One year of treatment with entecavir (0.5 mg daily) in nucleoside‐naive patients with hepatitis B e antigen (HBeAg)‐positive or… Expand Sustained virologic suppression is a primary goal of therapy for chronic hepatitis B (CHB). In study entecavir (ETV)‐022, 48… Expand Patients with chronic hepatitis B virus (HBV) infection who develop antiviral resistance lose benefits of therapy and may be… Expand BACKGROUND & AIMS
Entecavir demonstrated superior benefit to lamivudine at 48 weeks in nucleoside-naive patients with hepatitis B… Expand BACKGROUND
Entecavir is a potent and selective guanosine analogue with significant activity against hepatitis B virus (HBV… Expand BACKGROUND
Entecavir is a potent and selective antiviral agent that has demonstrated efficacy in phase 2 studies in patients with… Expand Summary. Hepatitis B virus (HBV) infection is a serious global health problem, with 2 billion people infected worldwide, and 350… Expand